Abdominal Candidiasis Is a Hidden Reservoir of Echinocandin Resistance

被引：94
作者：
Shields, Ryan K. [1 ,2 ]
Hong Nguyen, M. [1 ,2 ]
Press, Ellen G. [1 ]
Clancy, Cornelius J. [1 ,3 ]
机构：
[1] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA
[2] Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA
[3] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2014年 / 58卷 / 12期
基金：
美国国家卫生研究院;
关键词：
INVASIVE CANDIDIASIS; CASPOFUNGIN MICS; GLABRATA; OUTCOMES; THERAPY; SUSCEPTIBILITY; PERSISTENCE; CANDIDEMIA; MICAFUNGIN; FAILURE;
D O I：
10.1128/AAC.04134-14
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
FKS mutant Candida isolates were recovered from 24% (6/25) of abdominal candidiasis patients exposed to echinocandin. Candida glabrata (29%) and Candida albicans (14%) mutants were identified. Multidrug-resistant bacteria were recovered from 83% of FKS mutant infections. Mutations were associated with prolonged echinocandin exposure (P = 0.01), breakthrough infections (P = 0.03), and therapeutic failures despite source control interventions (100%). Abdominal candidiasis is a hidden reservoir for the emergence of echinocandin-resistant Candida.
引用
收藏
页码：7601 / 7605
页数：5
相关论文
共 19 条
  • [1] Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations
    Alexander, Barbara D.
    Johnson, Melissa D.
    Pfeiffer, Christopher D.
    Jimenez-Ortigosa, Cristina
    Catania, Jelena
    Booker, Rachel
    Castanheira, Mariana
    Messer, Shawn A.
    Perlin, David S.
    Pfaller, Michael A.
    [J]. CLINICAL INFECTIOUS DISEASES, 2013, 56 (12) : 1724 - 1732
  • [2] Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials
    Andes, David R.
    Safdar, Nasia
    Baddley, John W.
    Playford, Geoffrey
    Reboli, Annette C.
    Rex, John H.
    Sobel, Jack D.
    Pappas, Peter G.
    Kullberg, Bart Jan
    [J]. CLINICAL INFECTIOUS DISEASES, 2012, 54 (08) : 1110 - 1122
  • [3] [Anonymous], 2012, M27S4 CLSI
  • [4] FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
    Beyda, Nicholas D.
    John, Julie
    Kilic, Abdullah
    Alam, Mohammad J.
    Lasco, Todd M.
    Garey, Kevin W.
    [J]. CLINICAL INFECTIOUS DISEASES, 2014, 59 (06) : 819 - 825
  • [5] Candida Peritonitis: An Update on the Latest Research and Treatments
    Carneiro, Herman Anthony
    Mavrakis, Anastasios
    Mylonakis, Eleftherios
    [J]. WORLD JOURNAL OF SURGERY, 2011, 35 (12) : 2650 - 2659
  • [6] Candida glabrata Intra-Abdominal Candidiasis Is Characterized by Persistence within the Peritoneal Cavity and Abscesses
    Cheng, Shaoji
    Clancy, Cornelius J.
    Hartman, Douglas J.
    Hao, Binghua
    Nguyen, M. Hong
    [J]. INFECTION AND IMMUNITY, 2014, 82 (07) : 3015 - 3022
  • [7] In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole
    Clancy, Cornelius J.
    Staley, Benjamin
    Nguyen, M. Hong
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) : 3496 - 3498
  • [8] Undiagnosed invasive candidiasis: incorporating non-culture diagnostics into rational prophylactic and preemptive antifungal strategies
    Clancy, Cornelius J.
    Minh Hong Nguyen
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2014, 12 (07) : 731 - 734
  • [9] Real-World Experience with Echinocandin MICs against Candida Species in a Multicenter Study of Hospitals That Routinely Perform Susceptibility Testing of Bloodstream Isolates
    Eschenauer, Gregory A.
    Nguyen, M. Hong
    Shoham, Shmuel
    Vazquez, Jose A.
    Morris, Arthur J.
    Pasculle, William A.
    Kubin, Christine J.
    Klinker, Kenneth P.
    Carver, Peggy L.
    Hanson, Kimberly E.
    Chen, Sharon
    Lam, Simon W.
    Potoski, Brian A.
    Clarke, Lloyd G.
    Shields, Ryan K.
    Clancy, Cornelius J.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (04) : 1897 - 1906
  • [10] Interlaboratory Variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST Methods: Should the Clinical Laboratory Be Testing This Agent?
    Espinel-Ingroff, A.
    Arendrup, M. C.
    Pfaller, M. A.
    Bonfietti, L. X.
    Bustamante, B.
    Canton, E.
    Chryssanthou, E.
    Cuenca-Estrella, M.
    Dannaoui, E.
    Fothergill, A.
    Fuller, J.
    Gaustad, P.
    Gonzalez, G. M.
    Guarro, J.
    Lass-Floerl, C.
    Lockhart, S. R.
    Meis, J. F.
    Moore, C. B.
    Ostrosky-Zeichner, L.
    Pelaez, T.
    Pukinskas, S. R. B. S.
    St-Germain, G.
    Szeszs, M. W.
    Turnidge, J.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (12) : 5836 - 5842
12